The management of breast cancer involves various therapeutic approaches. However, many current anticancer treatments indiscriminately damage both cancerous and healthy cells. In cancer treatment, ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and ...

Introduction of wild-type (wt) p53 by means of adenoviral vectors has been shown to inhibit, both in vitro and in mouse xenograft models, the growth of various types of tumors. We have shown that ...

The effects of OR3 on xenograft mouse models were evaluated by tumor volume measurement, hematological analysis, and histopathological observation. The characterization of OR3 was also performed ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for ...